NCT06600711

Nitazoxanide for Treatment of Cryptosporidium in Children

Randomized Control Trial of Nitazoxanide for the Treatment of Cryptosporidium Infection in Malnourished Children in Bangladesh

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 480 (estimated)
• Sponsor: Johns Hopkins Bloomberg School of Public Health · Academic / Other
• Sex: All
• Age: 6 Months – 12 Months
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if nitazoxanide (NTZ) can treat Cryptosporidium infection in children age 6-12 months. The main questions it aims to answer are: * Does NTZ treatment of diarrheal Cryptosporidium infection lower the number of days of diarrhea? * Does NTZ treatment of diarrheal and non-diarrheal Cryptosporidium infection lower the number of days that parasites can be found in the stool? Researchers will compare NTZ to a placebo (a look-alike substance that contains no drug) to see if NTZ works to treat Cryptosporidium. Participants will: * Take NTZ or placebo for 3 days * Receive regular visits from field research assistants * Provide blood and urine samples

Conditions

• Cryptosporidiosis

Interventions

Type	Name	Description
DRUG	Nitazoxanide	5 mL suspension (100 mg), 2x/day for 3 days
DRUG	Placebo	identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days

Timeline

• Start date: 2026-06-30
• Primary completion: 2028-12-01
• Completion: 2030-05-01
• First posted: 2024-09-19
• Last updated: 2026-04-17